Grandfield & Dodd LLC Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

Grandfield & Dodd LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 35,205 shares of the biopharmaceutical company’s stock after purchasing an additional 1,998 shares during the quarter. Grandfield & Dodd LLC’s holdings in Regeneron Pharmaceuticals were worth $18,483,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of REGN. Proficio Capital Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 19 shares during the last quarter. Cove Private Wealth LLC lifted its stake in Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 20 shares during the last quarter. Marino Stram & Associates LLC grew its position in shares of Regeneron Pharmaceuticals by 5.3% during the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 20 shares during the last quarter. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Finally, CX Institutional increased its holdings in shares of Regeneron Pharmaceuticals by 7.9% in the 2nd quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 22 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Citigroup boosted their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $789.91.

Regeneron Pharmaceuticals Trading Up 1.9%

NASDAQ:REGN opened at $694.99 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $803.41. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $596.36 and a 200-day simple moving average of $570.46. The company has a market capitalization of $73.04 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the business posted $12.46 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.